59 results about "Moxidectin" patented technology

The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronization preparation. The synchronization preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.

The invention relates to a method for preparing high-purity Moxidectin, which comprises the following steps: (1) macroporous absorption resin chromatography is carried out on Moxidectin solution which is purified in advance, the obtained product is eluted by the mixed solution of polar organic solvent and water; (2) the eluent is extracted by methylene dichloride, and then solvent is removed by conventional concentration; (3) protective reaction is carried out on the condensate to obtain upper protective liquid; (4) macroporous absorption resin chromatography is carried out on the upper protective liquid, and the chromatography is eluted by the mixed solution of the polar organic solvent and the water; (5) the eluted upper protective liquid is oxidized, and then deprotection and oximation reaction are carried out to obtain the reaction liquid of the Moxidectin; (6) macroporous absorption resin chromatography is carried out on the reaction liquid of the Moxidectin, and the chromatography is eluted by the mixed solution of the polar organic solvent and the water, so that the obtained eluent is the high-purity Moxidectin solution; the product can be separated out of the solution by using the conventional concentration and crystallization technology if necessary. As the macroporous absorption resin chromatography is used for separating instead of silica gel chromatography, the method is not only stable and controllable as well as is easy to industrialize, but also improves the product purity, the quality and the yield.

Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.

High load concentrate compositions comprising metaflumizone, a substantially water-insoluble anti-parasitic macrolide compound,such as moxidectin, an optional bridging agent, a surfactant, and a suitable carrier solvent are prepared. These compositions may be topically administered to animals, and are useful for preventing or treating ectoparasitic infestations in warm-blooded animals for prolonged periods of time. Additionally, they may be further diluted to provide other types of formulations useable for both topical and oral administration.

A spot-on pesticide composition for animals, specifically mammals, namely dogs, which composition comprises a combination of a pyrethroid and a macrocyclic lactone selected from avermectin, ivermectin, selamectin, moxidectin, milbemycin and any combination thereof, and optionally fipronil and / or an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area.

This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals.

The present invention relates to methods of treating a mycobacterial infection. In particular, this invention relates to methods, uses and compounds for use in treating mycobacterial infections, including tuberculosis. For example, the compounds may be an avermectin or a milbemycin. The avermectin or milbemycin may be selected from, but not limited to, one or more of ivermectin, moxidectin or selamectin. Exemplary microbial infections that may be treated include, but are not limited to, infections caused by Mycobacterium tuberculosis, Mycobacterium bovis, other mycobacteria of the tuberculosis complex, and non-tuberculous mycobacteria, including Mycobacterium ulcerans.

The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.

The invention relates to a moxidectin preparation and a preparing method of the moxidectin preparation. The moxidectin preparation and the preparing method of the moxidectin preparation are efficient and can be stored for long time. The moxidectin preparation comprises, by weight, 100-300 parts of moxidectin, 1-5 parts of rhodium coordination compounds, 1-5 parts of preservative, 500-700 parts of water, 5-10 parts of surface active agents, 100-400 parts of methanol, and 10-50 parts of ethyl acetate. In the preparing process, the temperature of fermentation liquor rises to 600 DEG C at first, then fermentation liquor filter aid is added, plate-frame pressure filtration is carried out to collect filter cakes, filter liquid is left for sewage treatment, the filter cakes are dried to obtain dry mycelia, stock solution is obtained after procedures of digestion, resin absorption, elution and centrifugation, and the moxidectin preparation is obtained after granulation, drying and packaging.

The invention prepares high load concentrate compositions comprising metaflumizone, a substantially water-insoluble anti-parasitic macrolide compound,such as moxidectin, an optional bridging agent, a surfactant, and a suitable carrier solvent are prepared. These compositions may be topically administered to animals, and are useful for preventing or treating ectoparasitic infestations in warm-blooded animals for prolonged periods of time. Additionally, they may be further diluted to provide other types of formulations useable for both topical and oral administration.

The present invention provides a safe and effective process for the selective oxidation of a 5-O-protected-LLF-28249-α compound to the corresponding 23-keto compound of formula I wherein R is a protecting group. The present invention also provides the use of the selective oxidation process in the manufacture of moxidectin.

The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 microns. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3-6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.

The present invention provides a stable veterinary oral composition which comprises one or more surfactants, a water-miscible solvent, optionally an oil and an effective amount of each of a benzimidazole antihelmintic compound, such as triclabendazole and a macrocyclic lactone, such as moxidectin. Said composition is useful for treating and controlling endo- and ectoparasitic infection and infestation in a homeothermic animal.

The invention discloses a polyclonal antibody for detecting moxidectin as well as a preparation method and an application thereof. Firstly, a compound (a hapten) is protected, and a structural formula is shown in a formula (I). The invention also provides a conjugate obtained by conjugation of the compound shown in the formula (I) and a carrier protein. The invention also provides an antibody obtained by using the conjugate as an immunogen. The antibody is concretely a polyclonal antibody. The invention also provides a kit for detecting moxidectin, and the kit comprises the polyclonal antibody. The structure of moxidectin is reconstructed for the first time, the hapten is obtained, the polyclonal antibody of moxidectin is prepared, and home and abroad blanks are filled. The conjugate of the hapten and the carrier protein is used for preparing the moxidectin antibody, and the preparation process has the advantages of simplicity, economy, high sensitivity and high practical value. The product has good application prospects in the residual detection of veterinary drug.